Just fishing for opinions here... grateful for responses.
1) Does anyone think LANI could get accelerated approval in FDA based on the Japanese trials? This latest one used a whopping 1500 patients. If not straight approval, perhaps allowing the drug to skip phase II?
2) Does anyone know if the ROW license is a 50:50 split? I've seen analyst reports mentioning this, however commentary in announcements keep using the word "shared" rather than shared equally.
3) Given the market is confirmed blockbuster, what kind of royalty/milestone payments could we expect? I've seen cancer drugs get USD1bn upfront and up to 50% royalties. Is this feasible for LANI?
- Example, if fixed costs for LANI is $5 per pack, variable costs $1 per pack and Licensee profit margin is $5 per pack then a 50% royalty would put the price at $22 per pack. The larger the market the lower the fixed cost allocation per unit and higher the licensee profit margin. Alternatively they could just charge a higher price for the better drug keeping the licensee profit margin constant per dose.
BTA Price at posting:
$1.38 Sentiment: Buy Disclosure: Held
